BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36882165)

  • 1. ARID1A mutations in cancer development: mechanism and therapy.
    Zhang X; Zhang Y; Zhao J; Wu Y; Zhang N; Shen W
    Carcinogenesis; 2023 May; 44(3):197-208. PubMed ID: 36882165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential therapeutic targets in ARID1A-mutated cancers.
    Bitler BG; Fatkhutdinov N; Zhang R
    Expert Opin Ther Targets; 2015; 19(11):1419-22. PubMed ID: 26125128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
    Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
    BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of ARID1A in Endometrial Cancer and the Molecular Pathways Associated With Pathogenesis and Cancer Progression.
    Toumpeki C; Liberis A; Tsirkas I; Tsirka T; Kalagasidou S; Inagamova L; Anthoulaki X; Tsatsaris G; Kontomanolis EN
    In Vivo; 2019; 33(3):659-667. PubMed ID: 31028182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor suppressor role of chromatin-remodeling factor ARID1A].
    Guo XQ; Zhang QX; Huang WR; Duan XL; Cai ZM
    Yi Chuan; 2013 Mar; 35(3):255-61. PubMed ID: 23575531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications.
    Jin F; Yang Z; Shao J; Tao J; Reißfelder C; Loges S; Zhu L; Schölch S
    Trends Mol Med; 2023 Aug; 29(8):646-658. PubMed ID: 37179132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.
    Mandal J; Mandal P; Wang TL; Shih IM
    J Biomed Sci; 2022 Sep; 29(1):71. PubMed ID: 36123603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of ARID1A mutation on molecular characteristics in colorectal cancer.
    Tokunaga R; Xiu J; Goldberg RM; Philip PA; Seeber A; Battaglin F; Arai H; Lo JH; Naseem M; Puccini A; Berger MD; Soni S; Zhang W; Chen S; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
    Eur J Cancer; 2020 Nov; 140():119-129. PubMed ID: 33080474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARID1A loss in cancer: Towards a mechanistic understanding.
    Mathur R
    Pharmacol Ther; 2018 Oct; 190():15-23. PubMed ID: 29730444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of the AT-Rich Interaction Domain 1A Gene (
    Li JJ; Lee CS
    Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38275587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
    Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
    Elife; 2017 Oct; 6():. PubMed ID: 28967863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic significance of ARID1A mutation in bladder cancer.
    Conde M; Frew IJ
    Neoplasia; 2022 Sep; 31():100814. PubMed ID: 35750014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting ARID1A mutations in cancer.
    Mullen J; Kato S; Sicklick JK; Kurzrock R
    Cancer Treat Rev; 2021 Nov; 100():102287. PubMed ID: 34619527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARID1A mutations in cancer: another epigenetic tumor suppressor?
    Wu JN; Roberts CW
    Cancer Discov; 2013 Jan; 3(1):35-43. PubMed ID: 23208470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.
    Bosse T; ter Haar NT; Seeber LM; v Diest PJ; Hes FJ; Vasen HF; Nout RA; Creutzberg CL; Morreau H; Smit VT
    Mod Pathol; 2013 Nov; 26(11):1525-35. PubMed ID: 23702729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging roles of ARID1A in tumor suppression.
    Wu RC; Wang TL; Shih IeM
    Cancer Biol Ther; 2014 Jun; 15(6):655-64. PubMed ID: 24618703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress.
    Tomihara H; Carbone F; Perelli L; Huang JK; Soeung M; Rose JL; Robinson FS; Lissanu Deribe Y; Feng N; Takeda M; Inoue A; Poggetto ED; Deem AK; Maitra A; Msaouel P; Tannir NM; Draetta GF; Viale A; Heffernan TP; Bristow CA; Carugo A; Genovese G
    Cancer Res; 2021 Jan; 81(2):332-343. PubMed ID: 33158812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells.
    Suryo Rahmanto Y; Jung JG; Wu RC; Kobayashi Y; Heaphy CM; Meeker AK; Wang TL; Shih IeM
    J Biol Chem; 2016 Apr; 291(18):9690-9. PubMed ID: 26953344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
    Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
    Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer.
    Oike T; Ogiwara H; Nakano T; Yokota J; Kohno T
    Jpn J Clin Oncol; 2013 Sep; 43(9):849-55. PubMed ID: 23904343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.